<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02464033</url>
  </required_header>
  <id_info>
    <org_study_id>EDCR IIa</org_study_id>
    <nct_id>NCT02464033</nct_id>
  </id_info>
  <brief_title>EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes</brief_title>
  <official_title>Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd®), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnny Ludvigsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Child Diabetes Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ostergotland County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diamyd Medical AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Linkoeping University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study is to:

        -  Evaluate the tolerability of a combination therapy with Diamyd, vitamin D and etanercept

        -  Evaluate how the above mentioned treatments influence the immune system and endogenous
           insulin secretion
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">February 25, 2019</completion_date>
  <primary_completion_date type="Actual">February 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Reactions of the Injection Site as an Assessment of the Tolerability</measure>
    <time_frame>1 months</time_frame>
    <description>Number of patients with reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching, Other). Inspection of injection site 60 minutes after GAD-Alum injection by investigator or nurse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Reactions of the Injection Site as an Assessment of the Tolerability</measure>
    <time_frame>2 months</time_frame>
    <description>Number of patients with reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching, Other). Inspection of injection site 60 minutes after GAD-Alum injection by investigator or nurse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Any Abnormal Findings From Physical Examinations After Baseline</measure>
    <time_frame>Month 1, 2, 3, 6, 9, 15 and 30</time_frame>
    <description>Number of patients with any abnormal findings from physical examinations after baseline, including neurological assessments as an assessment of tolerability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Clinically Significant Laboratory Findings</measure>
    <time_frame>Month 1, 2, 3, 6, 9, 15 and 30</time_frame>
    <description>Number of patients with clinically significant laboratory findings, laboratory measurements as an assessment of the tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)</measure>
    <time_frame>6 months</time_frame>
    <description>GAD65AB titer (GADA) change from baseline. GAD65AB = Antibodies to GAD with molecular mass 65000</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)</measure>
    <time_frame>15 months</time_frame>
    <description>GAD65AB titer (GADA) change from baseline. GAD65AB = Antibodies to GAD with molecular mass 65000</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)</measure>
    <time_frame>30 months</time_frame>
    <description>GAD65AB titer (GADA) change from baseline. GAD65AB = Antibodies to GAD with molecular mass 65000</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With an Infection Reported as Adverse Event Related to Study Treatment</measure>
    <time_frame>Month 1, 2, 3, 6, 9, 15 and 30</time_frame>
    <description>Number of patients with an infection reported as Adverse Event related to study treatment (GAD-Alum and/or Etanercept),as an assessment of the tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline</measure>
    <time_frame>Baseline and 6 months at 0, 30, 60, 90 and 120 minutes post-dose</time_frame>
    <description>Weighted mean C-peptide: (AUC mean 0-120 min) during an MMTT, change from baseline to 6 months. MMTT=Mixed Meal Tolerance Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline</measure>
    <time_frame>Baseline and 15 months at 0, 30, 60, 90 and 120 minutes post-dose</time_frame>
    <description>Weighted mean C-peptide: (AUC mean 0-120 min) during an MMTT, change from baseline to 15 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline</measure>
    <time_frame>Baseline and 30 months at 0, 30, 60, 90 and 120 minutes post-dose</time_frame>
    <description>Weighted mean C-peptide: (AUC mean 0-120 min) during an MMTT, change from baseline to 30 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with a stimulated maximum C-peptide level above 0.2 nmol/L at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L</measure>
    <time_frame>15 months</time_frame>
    <description>Number of patients with a stimulated maximum C-peptide level above 0.2 nmol/L at 15 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L</measure>
    <time_frame>30 months</time_frame>
    <description>Number of patients with a stimulated maximum C-peptide level above 0.2 nmol/L at 30 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c (HbA1c), Change From Baseline</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Hemoglobin A1c (HbA1c), change from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c (HbA1c), Change From Baseline</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>Hemoglobin A1c (HbA1c), change from baseline to 15 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c (HbA1c), Change From Baseline</measure>
    <time_frame>Baseline and 30 months</time_frame>
    <description>Hemoglobin A1c (HbA1c), change from baseline to 30 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Exogenous 24-hour insulin dose per kg body weight and 24 hours average, change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>Exogenous 24-hour insulin dose per kg body weight and 24 hours average, change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline</measure>
    <time_frame>Baseline and 30 months</time_frame>
    <description>Exogenous 24-hour insulin dose per kg body weight and 24 hours average, change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide: Stimulated, 90 Minute Value, Change From Baseline</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>C-peptide: Stimulated, 90 minute value, change from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide: Stimulated, 90 Minute Value, Change From Baseline</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>C-peptide: Stimulated, 90 minute value, change from baseline to 15 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide: Stimulated, 90 Minute Value, Change From Baseline</measure>
    <time_frame>Baseline and 30 months</time_frame>
    <description>C-peptide: Stimulated, 90 minute value, change from baseline to 30 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide Fasting Concentration, Change From Baseline</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>C-peptide: Fasting concentration, change from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide Fasting Concentration, Change From Baseline</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>C-peptide: Fasting, concentration, change from baseline to 15 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide Fasting Concentration, Change From Baseline</measure>
    <time_frame>Baseline and 30 months</time_frame>
    <description>C-peptide: Fasting, concentration, change from baseline to 30 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Immune System Markers From Baseline to Month 6 (Main Study Period) and Subsequent Visits During the Extension Study Period</measure>
    <time_frame>Baseline and 6, 9, 15 and 30 months</time_frame>
    <description>Inflammatory markers, (e.g. TNF-alfa, IL-1 beta, IL-2, IL-17); Th2-deviation of cell-mediated immune response seen e.g. as increased ratio IL-5,10, 13 in comparison with IFN-gamma, TNF-alfa, IL-1 beta and IL-17; Regulatory T-cells. TNF=Tumor necrosis factor , IL=Interleukin, IFN=Interferon</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GAD-Alum</intervention_name>
    <description>Recombinant Human Glutamic Acid Decarboxylase (rhGAD65)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Diamyd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>A</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent given by patients and parent(s)/legal guardian(s)

          2. Type 1 diabetes according to the ADA classification, diagnosed within the previous 100
             days at the time of screening

          3. Age 8.00 -17.99 years at time of screening

          4. Fasting C-peptide at time of screening ≥0.12 nmol/L

          5. Positive for GADA but &lt; 50 000 Units

          6. Menarchal females must agree to avoid pregnancy and have a negative urine pregnancy
             test

          7. Immunity against Varicella, either through previous infection or vaccination

          8. Patients must follow the Swedish vaccination programme

          9. Patients of childbearing potential must agree to using adequate contraception, if
             sexually active, until 1 year after the last administration of GAD-alum and
             etanercept. Adequate contraception is as follows:

        For females of childbearing potential:

          1. oral (except low-dose gestagen (lynestrenol and norethisterone), injectable, or
             implanted hormonal contraceptives (females)

          2. intrauterine device (females)

          3. intrauterine system (for example, progestin-releasing coil) (females)

          4. vasectomized male (with appropriate postvasectomy documentation of the absence of
             sperm in the ejaculate)

        For males of childbearing potential:

        a. Condom (male)

        Exclusion Criteria:

          1. Previous or current treatment with immunosuppressant therapy (although topical or
             inhaled steroids are accepted)

          2. Continuous treatment with anti-inflammatory drug (sporadic treatment e.g. because of
             headache or in connection with fever a few days will be accepted)

          3. Treatment with any oral or injected anti-diabetic medications (especially hypoglycemic
             agents) other than insulin

          4. Treatment with Vitamin D, marketed or not, or unwilling to abstain from such
             medication during the trial

          5. A history of hypercalcemia

          6. A history of anaemia or significantly abnormal haematology results at screening

          7. A history of epilepsy, head trauma or cerebro-vascular accident, or clinical features
             of continuous motor unit activity in proximal muscles

          8. Clinically significant history of acute reaction to vaccines or other drugs in the
             past

          9. Treatment with any vaccine within 4 months prior to planned first administration of
             GAD-Alum or planned treatment with vaccine up to 4 months after the last injection
             with GAD-Alum, including influenza vaccine

         10. Participation in other clinical trials with a new chemical entity within the previous
             3 months

         11. Inability or unwillingness to comply with the provisions of this protocol

         12. A history of alcohol or drug abuse

         13. A significant illness other than diabetes within 2 weeks prior to first dosing

         14. Known human immunodeficiency virus (HIV)

         15. Prior or active viral hepatitis B or C infection

         16. Females who are lactating or pregnant (for females who have started menstruating the
             possibility of pregnancy must be excluded by urine βHCG on-site within 24 hours prior
             to the GAD-Alum and etanercept administration, respectively)

         17. Males or females not willing to use adequate contraception, if sexually active, until
             1 year after the last GAD-Alum and etanercept administration, respectively

         18. Presence of associated serious disease or condition, including active skin infections
             that preclude subcutaneous injection, which in the opinion of the investigator makes
             the patient non-eligible for the study.

         19. Deemed by the investigator not being able to follow instructions and/or follow the
             study protocol

         20. Active infection, including chronic and local infection or a history of previous
             tendency to serious infections, recent or ongoing uncontrolled bacterial, viral,
             fungal or other opportunistic infections, or known infection with active EBV or CMV

         21. Hypersensitivity to the active substance in Enbrel (etanercept) or other ingredients
             in Enbrel

         22. Active or inactive (latent) tuberculosis (TBC) at screening

         23. History of malignancy or significant cardiovascular disease

         24. Current or history of leukopenia, anemia and/or thrombocytopenia

         25. Liver disease (clinical or hepatic enzymes &gt;3 times the upper limit of normal (ULN))

         26. Renal insufficiency (clinical or creatinine &gt;3 times the upper limit of normal (ULN))

         27. MS, undefined neurologic condition or known SLE, or anti-nuclear or known
             doublestranded DNA antibody positivity

         28. Arrhythmia

         29. Pancreatitis

         30. Vitamin D serum levels &gt;100 nmol/L at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnny Ludvigsson, MD,PhD,Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linkoeping University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital, UMAS</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sachsska, Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uddevalla Hospital</name>
      <address>
        <city>Uddevalla</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Västerås Hospital</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <results_first_submitted>June 10, 2019</results_first_submitted>
  <results_first_submitted_qc>September 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2019</results_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Linkoeping University</investigator_affiliation>
    <investigator_full_name>Johnny Ludvigsson</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>Diamyd</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Juvenile Diabetes</keyword>
  <keyword>Diabetes Type 1</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Autoimmune Diabetes</keyword>
  <keyword>Insulin Dependent Diabetes</keyword>
  <keyword>Type 1 Diabetes MellitusType 1 Diabetes Mellitus</keyword>
  <keyword>rhGAD65</keyword>
  <keyword>GAD65</keyword>
  <keyword>GAD-Alum</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes mellitus Type 1</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Etanercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 17, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02464033/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GAD-Alum+Vitamin D+Etanercept</title>
          <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GAD-Alum+Vitamin D+Etanercept</title>
          <description>All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.36" spread="2.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type 1 Diabetes duration</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.35" spread="22.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.38" spread="2.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Reactions of the Injection Site as an Assessment of the Tolerability</title>
        <description>Number of patients with reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching, Other). Inspection of injection site 60 minutes after GAD-Alum injection by investigator or nurse</description>
        <time_frame>1 months</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Reactions of the Injection Site as an Assessment of the Tolerability</title>
          <description>Number of patients with reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching, Other). Inspection of injection site 60 minutes after GAD-Alum injection by investigator or nurse</description>
          <population>Safety</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Reactions of the Injection Site as an Assessment of the Tolerability</title>
        <description>Number of patients with reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching, Other). Inspection of injection site 60 minutes after GAD-Alum injection by investigator or nurse</description>
        <time_frame>2 months</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Reactions of the Injection Site as an Assessment of the Tolerability</title>
          <description>Number of patients with reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching, Other). Inspection of injection site 60 minutes after GAD-Alum injection by investigator or nurse</description>
          <population>Safety</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Any Abnormal Findings From Physical Examinations After Baseline</title>
        <description>Number of patients with any abnormal findings from physical examinations after baseline, including neurological assessments as an assessment of tolerability.</description>
        <time_frame>Month 1, 2, 3, 6, 9, 15 and 30</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Any Abnormal Findings From Physical Examinations After Baseline</title>
          <description>Number of patients with any abnormal findings from physical examinations after baseline, including neurological assessments as an assessment of tolerability.</description>
          <population>Safety</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Clinically Significant Laboratory Findings</title>
        <description>Number of patients with clinically significant laboratory findings, laboratory measurements as an assessment of the tolerability</description>
        <time_frame>Month 1, 2, 3, 6, 9, 15 and 30</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Clinically Significant Laboratory Findings</title>
          <description>Number of patients with clinically significant laboratory findings, laboratory measurements as an assessment of the tolerability</description>
          <population>Safety</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)</title>
        <description>GAD65AB titer (GADA) change from baseline. GAD65AB = Antibodies to GAD with molecular mass 65000</description>
        <time_frame>6 months</time_frame>
        <population>Intention To Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)</title>
          <description>GAD65AB titer (GADA) change from baseline. GAD65AB = Antibodies to GAD with molecular mass 65000</description>
          <population>Intention To Treat (ITT)</population>
          <units>U/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2509.41" spread="4866.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)</title>
        <description>GAD65AB titer (GADA) change from baseline. GAD65AB = Antibodies to GAD with molecular mass 65000</description>
        <time_frame>15 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)</title>
          <description>GAD65AB titer (GADA) change from baseline. GAD65AB = Antibodies to GAD with molecular mass 65000</description>
          <population>ITT</population>
          <units>U/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1036.19" spread="2527.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)</title>
        <description>GAD65AB titer (GADA) change from baseline. GAD65AB = Antibodies to GAD with molecular mass 65000</description>
        <time_frame>30 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)</title>
          <description>GAD65AB titer (GADA) change from baseline. GAD65AB = Antibodies to GAD with molecular mass 65000</description>
          <population>ITT</population>
          <units>U/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347.01" spread="1564.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With an Infection Reported as Adverse Event Related to Study Treatment</title>
        <description>Number of patients with an infection reported as Adverse Event related to study treatment (GAD-Alum and/or Etanercept),as an assessment of the tolerability</description>
        <time_frame>Month 1, 2, 3, 6, 9, 15 and 30</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With an Infection Reported as Adverse Event Related to Study Treatment</title>
          <description>Number of patients with an infection reported as Adverse Event related to study treatment (GAD-Alum and/or Etanercept),as an assessment of the tolerability</description>
          <population>Safety</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline</title>
        <description>Weighted mean C-peptide: (AUC mean 0-120 min) during an MMTT, change from baseline to 6 months. MMTT=Mixed Meal Tolerance Test</description>
        <time_frame>Baseline and 6 months at 0, 30, 60, 90 and 120 minutes post-dose</time_frame>
        <population>ITT, MMTT not performed for 2 patients hence no data available for 2 out of the 20 patients</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline</title>
          <description>Weighted mean C-peptide: (AUC mean 0-120 min) during an MMTT, change from baseline to 6 months. MMTT=Mixed Meal Tolerance Test</description>
          <population>ITT, MMTT not performed for 2 patients hence no data available for 2 out of the 20 patients</population>
          <units>nmol/L*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline</title>
        <description>Weighted mean C-peptide: (AUC mean 0-120 min) during an MMTT, change from baseline to 15 months</description>
        <time_frame>Baseline and 15 months at 0, 30, 60, 90 and 120 minutes post-dose</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline</title>
          <description>Weighted mean C-peptide: (AUC mean 0-120 min) during an MMTT, change from baseline to 15 months</description>
          <population>ITT</population>
          <units>nmol/L*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline</title>
        <description>Weighted mean C-peptide: (AUC mean 0-120 min) during an MMTT, change from baseline to 30 months</description>
        <time_frame>Baseline and 30 months at 0, 30, 60, 90 and 120 minutes post-dose</time_frame>
        <population>ITT, , MMTT not performed for 1 patient hence no data available for 1 out of the 20 patients</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline</title>
          <description>Weighted mean C-peptide: (AUC mean 0-120 min) during an MMTT, change from baseline to 30 months</description>
          <population>ITT, , MMTT not performed for 1 patient hence no data available for 1 out of the 20 patients</population>
          <units>nmol/L*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L</title>
        <description>Number of patients with a stimulated maximum C-peptide level above 0.2 nmol/L at 6 months</description>
        <time_frame>6 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L</title>
          <description>Number of patients with a stimulated maximum C-peptide level above 0.2 nmol/L at 6 months</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L</title>
        <description>Number of patients with a stimulated maximum C-peptide level above 0.2 nmol/L at 15 months</description>
        <time_frame>15 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L</title>
          <description>Number of patients with a stimulated maximum C-peptide level above 0.2 nmol/L at 15 months</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L</title>
        <description>Number of patients with a stimulated maximum C-peptide level above 0.2 nmol/L at 30 months</description>
        <time_frame>30 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L</title>
          <description>Number of patients with a stimulated maximum C-peptide level above 0.2 nmol/L at 30 months</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin A1c (HbA1c), Change From Baseline</title>
        <description>Hemoglobin A1c (HbA1c), change from baseline to 6 months</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c (HbA1c), Change From Baseline</title>
          <description>Hemoglobin A1c (HbA1c), change from baseline to 6 months</description>
          <population>ITT</population>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="8.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin A1c (HbA1c), Change From Baseline</title>
        <description>Hemoglobin A1c (HbA1c), change from baseline to 15 months</description>
        <time_frame>Baseline and 15 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c (HbA1c), Change From Baseline</title>
          <description>Hemoglobin A1c (HbA1c), change from baseline to 15 months</description>
          <population>ITT</population>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" spread="12.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin A1c (HbA1c), Change From Baseline</title>
        <description>Hemoglobin A1c (HbA1c), change from baseline to 30 months</description>
        <time_frame>Baseline and 30 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c (HbA1c), Change From Baseline</title>
          <description>Hemoglobin A1c (HbA1c), change from baseline to 30 months</description>
          <population>ITT</population>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.55" spread="11.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline</title>
        <description>Exogenous 24-hour insulin dose per kg body weight and 24 hours average, change from baseline</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline</title>
          <description>Exogenous 24-hour insulin dose per kg body weight and 24 hours average, change from baseline</description>
          <population>ITT</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline</title>
        <description>Exogenous 24-hour insulin dose per kg body weight and 24 hours average, change from baseline</description>
        <time_frame>Baseline and 15 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline</title>
          <description>Exogenous 24-hour insulin dose per kg body weight and 24 hours average, change from baseline</description>
          <population>ITT</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline</title>
        <description>Exogenous 24-hour insulin dose per kg body weight and 24 hours average, change from baseline</description>
        <time_frame>Baseline and 30 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline</title>
          <description>Exogenous 24-hour insulin dose per kg body weight and 24 hours average, change from baseline</description>
          <population>ITT</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-peptide: Stimulated, 90 Minute Value, Change From Baseline</title>
        <description>C-peptide: Stimulated, 90 minute value, change from baseline to 6 months</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>ITT, not performed for 2 patients hence no data available for 2 out of the 20 patients</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide: Stimulated, 90 Minute Value, Change From Baseline</title>
          <description>C-peptide: Stimulated, 90 minute value, change from baseline to 6 months</description>
          <population>ITT, not performed for 2 patients hence no data available for 2 out of the 20 patients</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-peptide: Stimulated, 90 Minute Value, Change From Baseline</title>
        <description>C-peptide: Stimulated, 90 minute value, change from baseline to 15 months</description>
        <time_frame>Baseline and 15 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide: Stimulated, 90 Minute Value, Change From Baseline</title>
          <description>C-peptide: Stimulated, 90 minute value, change from baseline to 15 months</description>
          <population>ITT</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-peptide: Stimulated, 90 Minute Value, Change From Baseline</title>
        <description>C-peptide: Stimulated, 90 minute value, change from baseline to 30 months</description>
        <time_frame>Baseline and 30 months</time_frame>
        <population>ITT, not performed for 1 patient hence no data available for 1 out of the 20 patients</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide: Stimulated, 90 Minute Value, Change From Baseline</title>
          <description>C-peptide: Stimulated, 90 minute value, change from baseline to 30 months</description>
          <population>ITT, not performed for 1 patient hence no data available for 1 out of the 20 patients</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-peptide Fasting Concentration, Change From Baseline</title>
        <description>C-peptide: Fasting concentration, change from baseline to 6 months</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide Fasting Concentration, Change From Baseline</title>
          <description>C-peptide: Fasting concentration, change from baseline to 6 months</description>
          <population>ITT</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-peptide Fasting Concentration, Change From Baseline</title>
        <description>C-peptide: Fasting, concentration, change from baseline to 15 months</description>
        <time_frame>Baseline and 15 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide Fasting Concentration, Change From Baseline</title>
          <description>C-peptide: Fasting, concentration, change from baseline to 15 months</description>
          <population>ITT</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-peptide Fasting Concentration, Change From Baseline</title>
        <description>C-peptide: Fasting, concentration, change from baseline to 30 months</description>
        <time_frame>Baseline and 30 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D+Etanercept</title>
            <description>All patients will from Day 1 receive 2000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide Fasting Concentration, Change From Baseline</title>
          <description>C-peptide: Fasting, concentration, change from baseline to 30 months</description>
          <population>ITT</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Immune System Markers From Baseline to Month 6 (Main Study Period) and Subsequent Visits During the Extension Study Period</title>
        <description>Inflammatory markers, (e.g. TNF-alfa, IL-1 beta, IL-2, IL-17); Th2-deviation of cell-mediated immune response seen e.g. as increased ratio IL-5,10, 13 in comparison with IFN-gamma, TNF-alfa, IL-1 beta and IL-17; Regulatory T-cells. TNF=Tumor necrosis factor , IL=Interleukin, IFN=Interferon</description>
        <time_frame>Baseline and 6, 9, 15 and 30 months</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 months</time_frame>
      <desc>Adverse Events were recorded in the Case Report Form at each clinic visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>GAD-Alum+Vitamin D+Etanercept</title>
          <description>All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
GAD-Alum
Vitamin D
Etanercept</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="30" subjects_affected="13" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Johnny Ludvigsson, MD, PhD, Prof Linkoeping University</name_or_title>
      <organization>Linkoeping University</organization>
      <phone>+46 13 28 68 54</phone>
      <email>Johnny.Ludvigsson@liu.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

